On August 22, 2023, the Federal Circuit made an affirmative decision in an inter partes review (IPR) Final Written Decision, classifying claims to deuterated derivatives of a drug named ruxolitinib as unpatentable due to their obvious nature. The ruling diminished the patentee’s argument that an individual with adequate skills in the field would not have been driven to modify the undisputed lead compound based on previous teachings exhibiting the general benefits of deuteration. This information was provided by Axinn, Veltrop & Harkrider LLP via a public document. The case was examined utilizing a lead compound analysis.
The lead compound analysis is a test used in determining the patentability of new chemical entities. The court applies this analysis in order to ascertain whether a chemist of ordinary skill would have chosen the particular lead compound or compounds as a starting point for further development efforts.
With respect to this case, deuterated derivatives of the medicine, ruxolitinib, were put under examination. For the uninitiated, ruxolitinib is a medication used for treating myelofibrosis, a serious bone marrow disorder that affects your body’s ability to produce blood cells. It gained importance owing to its impactful role in the pharmaceutical industry.
The argument presented by the patentee claimed that an experienced chemist would not have been inspired to experiment and alter the undisputed lead compound based on prior teachings, specifically those highlighting the general value of deuteration. Deuteration is a process in which hydrogen atoms in a molecule are replaced with deuterium, a heavier isotope of hydrogen, which can make a drug like ruxolitinib more effective and safer.
Despite this line of reasoning, the Federal Circuit confirmed the unpatentability of the deuterated derivatives of ruxolitinib, thus making a significant implication in the field of patent law. Changes such as this can alter the trajectory of the pharmaceutical industry and can potentially affect ongoing and future research initiatives concerning the development of new drugs.
For further details, you can read the full document here.